Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb).
- The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with chronic HBV.
- "The combination therapy achieved hepatitis B surface antigen (HBsAg) knockdown of more than 3 log10 IU/mL, an impressive result, particularly when compared to other combination and monotherapies studies, the analyst writes.
- The analyst says that the positive outcome has increased confidence in the program.
- The analyst views Vir & Alnylam as emerging as leaders in the chronic HBV treatment space estimated to exceed $100 billion in aggregate revenues over the next 15 years.
- The update on the Emergency Use Authorization (EUA) for sotrovimab, a monoclonal antibody (mAb) antiviral for early-stage COVID-19, can dent the enthusiasm.
- Related: Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here.
- Ahead of trial readouts amid upside potential on the HBV program in 2H22 and 2023, HC Wainwright reiterates a Buy rating and the price target of $200 on the stock.
- Price Action: VIR shares are down 3.12% at $19.72 during the market session on the last check Monday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!